Lot 2026/02 · Krause Analytical · reported 8 May 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterionAbove criterionNot on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
HPLC-UV-MS
Mass spectral match to the labelled compound
Confirmed
WITHIN SPEC
Chromatographic purity
HPLC-UV/MS
at or above 98.0%
>99.9 %
95at or above 98.0%100
WITHIN SPEC
Net content
HPLC-UV-MS
13.8 mg
80120
REPORTED
Endotoxin
LAL, USP <85>
below 0.5 EU/mL
<0.5 EU/mL
WITHIN SPEC
Values are reported per vial or bottle unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Krause Analytical · 3 pages · served inline, not a screenshot
Quick reference
How to read this report
Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your product label. If they differ, this report is not for your product.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much compound is in each vial or bottle, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile
GLP-3R, in structural terms.
Sequence
Modified 39-residue sequence: Y–Aib–QGTFTSDYSI–2-Me-Leu–LDK–[Lys(AEEA-γGlu-C20 diacid)]–AQAibAFIEYLLEGGPSSGAPPPS-NH₂ This is not a simple conventional amino-acid sequence because the molecule incorporates Aib residues, α-methyl-leucine, a modified lysine carrying a lipid-linked side chain, and a C-terminal serinamide. KEGG reports the 39-residue backbone and identifies the molecule as a modified peptide.
Molecular formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight
Approximately 4731.34 g/mol
CAS number
2381089-83-2
Structure type
Linear peptide
Primary molecular target
GLP-1 Receptor (GLP-1R) / GIP Receptor (GIPR) / Glucagon Receptor (GCGR) All three are established molecular targets of the reference compound.
GLP-3R is a synthetic 39-residue modified and lipidated peptide engineered for multi-receptor activity. Its structure incorporates noncanonical amino-acid modifications and a lipid-containing side chain. These modifications differentiate the molecule from naturally occurring GLP-1, GIP, and glucagon peptides and contribute to its distinctive triple-receptor pharmacology. IUPHAR/BPS describes the reference compound as a lipidated, modified peptide targeting GCGR, GIPR, and GLP-1R.KEGG reports this molecular formula, a molecular weight of 4731.34 and an exact mass of 4728.4718 for the reference modified peptide.
In preclinical and laboratory research models, GLP-3R has been examined across metabolic, endocrine, and systemic research systems. Research focus includes:
These observations are limited to controlled experimental environments and support ongoing laboratory investigations.
These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.
Cited literature
Brubaker PL et al., 2002. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. PMID 12529935. https://pubmed.ncbi.nlm.nih.gov/12529935/
Novikoff A et al., 2021. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab. PMID 33556643. https://pubmed.ncbi.nlm.nih.gov/33556643/
Dinsmore I et al., 2024. Potent and Protease Resistant Azapeptide Agonists of the GLP-1 and GIP Receptors. Angew Chem Int Ed Engl. PMID 39151024. https://pubmed.ncbi.nlm.nih.gov/39151024/
Evidence level
Published preclinical and early experimental research. This compound appears in the published receptor-pharmacology literature, predominantly in in-vitro binding and animal-model studies. This describes the evidence base around the molecule and does not imply approval or established efficacy.
Handling and storage
As supplied
Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.
Storage
Store per the conditions printed on the vial label. Avoid heat, moisture and repeated temperature cycling.
Handling
For qualified professionals in controlled laboratory environments, following validated laboratory procedures.
Frequently asked questions
About this compound and its batch data.
What purity did this GLP-3 batch achieve?
Lot 2026/02 was analysed by Krause Analytical and returned chromatographic purity of >99.9 % by HPLC with UV detection coupled to mass spectrometry. Identity was confirmed by mass spectral match. The full certificate is published on this page, and every figure shown here is taken from it.
How much GLP-3 is in the vial?
The laboratory measured 13.8 mg, which is 92% of the label claim. Net content is reported on a per-vial basis. Astramide publishes the measured figure rather than the label claim, whether it falls above or below.
Was this GLP-3 batch tested for endotoxins?
Yes. Endotoxin testing was performed using the Limulus Amebocyte Lysate assay in accordance with USP <85>, and this batch returned <0.5 EU/mL. The result appears on the certificate published on this page.
How should GLP-3 be stored for research use?
As supplied, the lyophilized powder should be held at -20°C and protected from light and moisture. Once reconstituted, store at 2-8°C and use within 14 to 30 days. Avoid repeated freeze-thaw cycles and follow the handling procedures appropriate to your laboratory.
What is the difference between research-grade and pharmaceutical-grade GLP-3?
These are separate classifications. Research-grade material is supplied for laboratory research use only and is not intended for human or animal consumption. Pharmaceutical-grade is an FDA classification that applies to drugs manufactured for human use. Astramide supplies research-grade material only.
How can I verify this GLP-3 certificate independently?
The certificate was issued by Krause Analytical under lot 2026/02, laboratory reference 205079. Quote that reference to the laboratory directly. The same document is published here in full, and is not summarised or reformatted by Astramide.
Research use only
This product is intended strictly for in-vitro laboratory research conducted by qualified professionals.
It is not intended for human or animal consumption, clinical use, or therapeutic application.
The statements on this page have not been reviewed by the FDA. These research peptides are not intended
to diagnose, treat, cure, or prevent any disease. Research Use Only.
Get It Now
This product has multiple variants. The options may be chosen on the product page
Added to your cart
Your cart is empty.
Your Privacy Choices
We use analytics and advertising tools to understand how visitors find us and which campaigns work. You can turn either off. Your choice is saved in this browser.
AnalyticsGoogle Analytics, Microsoft Clarity and order source tracking. Helps us see how the site is used and fix problems.
Off (browser signal)
AdvertisingMeta and X pixels, and server-side events. Opting out also opts you out of "sharing" and targeted advertising under state privacy laws.
Off (browser signal)
Your browser is sending a Global Privacy Control signal, so analytics and advertising are off. To change this, turn off the signal in your browser settings.
Strictly necessary cookies (cart, sign-in, checkout, entry acknowledgment) always stay on. See our Privacy Policy.
Know what's in it before you order.
Every Astramide batch is tested by an independent US lab. The report goes public before the batch goes on sale, so you can check the numbers first.
Independent US lab test on every batch
Full report published before it goes on sale
Kept frozen, shipped from Austin, Texas
GLP-3RLot 2026/02 · May 8, 2026
>99.9%purity by HPLC-UV/MS
90%Minimum 98.0%100%
Identity: Confirmed by mass specEndotoxin: Below 0.5 EU/mL
Pro Series
Pro Series
